Back

Incidence and predictors of 2-year mortality following percutaneous left atrial appendage occlusion in the EWOLUTION tria

31 August 2024 (17:00 - 17:50)
Organised by: Logo
Congress Presentation Part of: Left atrial appendix closure for stroke prevention in atrial fibrillation Left Atrial Appendage Closure ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Errol Aarnink

St Antonius Hospital, Nieuwegein (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Prevention of thromboembolic events in atrial fibrillation patients with persistent leaks following the watchman implantation
Doctor S. Mohanty (Austin, US)
Abstract Slides Video
Presentation thumbnail
Safety of left atrial appendage amputation during cardiothoracic surgery
Mr M. Terpstra (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Combined PVI and LAAC is feasible using RFA or PFA in a canine model despite acute tissue edema in PFA versus RFA
Doctor W. Saliba (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Impact of left atrial appendage occlusion in atrial flow evaluated through 4D flow cardiac magnetic resonance
Mr I. Anduaga Elorza (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Cardiac amyloidosis and left atrial appendage closure: a multicenter retrospective study
Doctor E. El-Am (Rochester, US)
Abstract Slides Video

Access the full session

Session thumbnail
Left atrial appendix closure for stroke prevention in atrial fibrillation

The Event

Event poster

ESC Congress 2024

31 August 2024 17:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-term Outcomes Following Left Atrial Appendage Occlusion with a Watchman Device: Outcomes from the National Cardiovascular Data Registry
thumbnail
Congress Session
Registries on atrial fibrillation and sudden death
thumbnail
Congress Presentation
Percutaneous left atrial appendage occlusion versus direct oral anticoagulation therapy in clinical practice: a propensity-score matched study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources